<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112159</url>
  </required_header>
  <id_info>
    <org_study_id>IPG1094-A001</org_study_id>
    <nct_id>NCT05112159</nct_id>
  </id_info>
  <brief_title>Study of IPG1094 in Healthy Participants</brief_title>
  <official_title>A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Orally Administered IPG1094 in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Immunophage Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Immunophage Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose&#xD;
      escalation study to evaluate the safety, tolerability, and PK of single dose orally&#xD;
      administered IPG1094 in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2021</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of all adverse events</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RBC</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>white blood cell count (WBC)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>platelet count (PLT)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>haemoglobin (HGB)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean corpuscular hemoglobin</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean corpuscular hemoglobin concentration</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean corpuscular volume (MCV)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>absolute differential leukocyte count (eosinophils)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>absolute differential leukocyte count (monocytes)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>absolute differential leukocyte count (lymphocytes)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>absolute differential leukocyte count (basophils)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>absolute differential leukocyte count (neutrophils)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Hematology</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature (Â°C )</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiration rate</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure (both systolic and diastolic)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Vital Signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard 12-lead ECG - heart rate</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Electrocardiograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard 12-lead ECG - QTcF</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Electrocardiograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard 12-lead ECG - PR</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Electrocardiograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard 12-lead ECG - QRS</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Electrocardiograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard 12-lead ECG - QT</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Electrocardiograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine aminotransferase (ALT)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>albumin (ALB)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>alkaline phosphatase (ALP)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>aspartate aminotransferase (AST)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total bilirubin (TBil)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urea</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>calcium (Ca)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chloride (Cl)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>cholesterol (CHO)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>creatinine (Cr)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>creatine kinase (CK)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose (Glu)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lactate dehydrogenase (LDH)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>phosphate (P)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>potassium (K)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sodium (Na)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total protein (TP)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Chemistry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prothrombin time (PT)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Coagulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>activated partial thromboplastin time (APTT)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Coagulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fibrinogen</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Coagulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>international normalized ratio (INR)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Serum Coagulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pH</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bilirubin (U-BIL)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose (GLU)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urine erythrocytes (U-RBC)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ketones (U-KET)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary leukocyte (U-LEU)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>nitrites (U-NIT)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>protein (U-PRO)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>specific gravity (U-SG)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>urobilinogen (URO)</measure>
    <time_frame>Up to 8 days</time_frame>
    <description>Evaluation of Urinalysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentrationï¼Cmaxï¼</measure>
    <time_frame>Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.</time_frame>
    <description>Pharmacokinetic (PK) parameters after a single oral dose of IPG1094</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (tmax)</measure>
    <time_frame>Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.</time_frame>
    <description>Pharmacokinetic (PK) parameters after a single oral dose of IPG1094</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC[0-t]</measure>
    <time_frame>Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.</time_frame>
    <description>Pharmacokinetic (PK) parameters after a single oral dose of IPG1094</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-infinity curve AUC[0-infinity]</measure>
    <time_frame>Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.</time_frame>
    <description>Pharmacokinetic (PK) parameters after a single oral dose of IPG1094</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal phase half-life (t1/2)</measure>
    <time_frame>Blood samples will be collected at 0 h before administration (within 1h prior to administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24, 36, 48, 72, and 96 h after administration.</time_frame>
    <description>Pharmacokinetic (PK) parameters after a single oral dose of IPG1094</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>IPG1094 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four subjects in this cohort will receive a single dose of IPG1094 100 mg qd and two subjects will receive a single dose of placebo 100mg qd orally. Sentinel subjects (i.e. 1 subject will be dosed with IPG1094 and 1 with placebo before the remainder of the cohort is dosed) will be used in the cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPG1094 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects in this cohort will receive a single dose of IPG1094 300 mg qd and two subjects will receive a single dose of placebo 300mg qd orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPG1094 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects in this cohort will receive a single dose of IPG1094 600 mg qd and two subjects will receive a single dose of placebo 600mg qd orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPG1094 900mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects in this cohort will receive a single dose of IPG1094 900 mg qd and two subjects will receive a single dose of placebo 900mg qd orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPG1094 1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects in this cohort will receive a single dose of IPG1094 1200 mg qd and two subjects will receive a single dose of placebo 1200 mg qd orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IPG1094 1500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six subjects in this cohort will receive a single dose of IPG1094 1500 mg qd and two subjects will receive a single dose of placebo 1500mg qd orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPG1094</intervention_name>
    <description>The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094.</description>
    <arm_group_label>IPG1094 100mg</arm_group_label>
    <arm_group_label>IPG1094 1200mg</arm_group_label>
    <arm_group_label>IPG1094 1500mg</arm_group_label>
    <arm_group_label>IPG1094 300mg</arm_group_label>
    <arm_group_label>IPG1094 600mg</arm_group_label>
    <arm_group_label>IPG1094 900mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Matching placebo tablets to IPG1094 50mg and 100mg</description>
    <arm_group_label>IPG1094 100mg</arm_group_label>
    <arm_group_label>IPG1094 1200mg</arm_group_label>
    <arm_group_label>IPG1094 1500mg</arm_group_label>
    <arm_group_label>IPG1094 300mg</arm_group_label>
    <arm_group_label>IPG1094 600mg</arm_group_label>
    <arm_group_label>IPG1094 900mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must meet all of the following criteria to be included in the study:&#xD;
&#xD;
        Demography&#xD;
&#xD;
          1. Healthy adult male or female participants between 18 and 50 years of age (inclusive).&#xD;
&#xD;
          2. Body weight between 50 and 100 kg (inclusive) and body mass index (BMI) within 18~32&#xD;
             kg/m2 (inclusive).&#xD;
&#xD;
             Health status&#xD;
&#xD;
          3. In good health as determined by screening tests. Good health is defined as having no&#xD;
             clinically relevant abnormalities identified by a detailed medical history, full&#xD;
             physical examination (including measurement of blood pressure and pulse rate), 12-lead&#xD;
             ECG, and clinical laboratory tests.&#xD;
&#xD;
             Vital signs (measured after resting for 5 minutes seated position) within normal&#xD;
             range, or outside the normal range and not considered clinically significant by the&#xD;
             Investigator.&#xD;
&#xD;
             Standard 12-lead ECG parameters (recorded after resting for 5 minutes in supine&#xD;
             position) in the following ranges; corrected QT interval(QTc) (Fridericia algorithm&#xD;
             recommended) â¤ 450 ms for males and 470 ms for females, and normal ECG tracing, or&#xD;
             abnormal ECG tracing not considered clinically relevant by the Investigator.&#xD;
&#xD;
             Laboratory parameters demonstrating no clinically significant abnormalities, as&#xD;
             determined by the Investigator. A total bilirubin outside the normal range may be&#xD;
             acceptable if total bilirubin does not exceed 1.5 Ã upper limit of normal(ULN)&#xD;
             conjugated bilirubin (with the exception of a participant with documented Gilbert&#xD;
             syndrome).&#xD;
&#xD;
          4. A negative result on urine drug screen and a repeat negative result on Day -1&#xD;
             (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine,&#xD;
             opiates).&#xD;
&#xD;
          5. Female participants must not be pregnant or breastfeeding and must use an effective&#xD;
             contraception method (as described in Section 4.5.4), with the exception of&#xD;
             participants who have undergone sterilization in the preceding 3 months, or who are&#xD;
             postmenopausal.&#xD;
&#xD;
             A woman of childbearing potential (WOCBP) must undergo pregnancy testing prior to the&#xD;
             first dose of the Investigational Medicinal Product (IMP). The participant must be&#xD;
             excluded from the study if the serum pregnancy test is positive.&#xD;
&#xD;
             A postmenopausal state is defined as 12 months of amenorrhea without an alternative&#xD;
             medical cause. In the absence of 12 months of amenorrhea, menopause may be confirmed&#xD;
             by follicle stimulating hormoneï¼FSHï¼ measurement (&gt; 40 IU/L or milli-International&#xD;
             unitï¼mIUï¼/mL).Females on Hormonal Replacement therapy (HRT ), where menopausal status&#xD;
             is indeterminate, will be required to use a non-estrogen hormonal contraceptive method&#xD;
             if participants wish to continue their HRT during the study. Participants must&#xD;
             otherwise discontinue HRT to allow for confirmation of postmenopausal status prior to&#xD;
             enrollment in the study.&#xD;
&#xD;
             Regulation&#xD;
&#xD;
          6. Provide written informed consent prior to undertaking any study-related procedures.&#xD;
&#xD;
          7. Must not be under any administrative or legal supervision or under&#xD;
             institutionalization as per a regulatory or juridical order.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants who meet any of the following criteria will be excluded from the study:&#xD;
&#xD;
        Medical history and clinical status&#xD;
&#xD;
          1. Any history or presence of clinically relevant cardiovascular, pulmonary,&#xD;
             gastrointestinal, hepatic, renal, metabolic, hematological, neurological,&#xD;
             musculoskeletal, rheumatological, psychiatric, systemic, ocular, or infectious&#xD;
             disease, or signs of acute illness.&#xD;
&#xD;
          2. Frequent severe headaches and/or migraines, recurrent nausea and/or vomiting (defined&#xD;
             as vomiting more than twice a month).&#xD;
&#xD;
          3. Made a blood donation of any volume within 2 months prior to the first dose.&#xD;
&#xD;
          4. Symptomatic postural hypotension, irrespective of actual decrease in blood pressure,&#xD;
             or asymptomatic postural hypotension with a decrease in systolic blood pressure â¥30&#xD;
             mmHg within 3 minutes of moving from supine to standing position.&#xD;
&#xD;
          5. Presence or history of drug hypersensitivity, or anaphylactic reaction, diagnosed and&#xD;
             treated by a physician.&#xD;
&#xD;
          6. Known hypersensitivity to any component of the IMP formulation.&#xD;
&#xD;
          7. History or presence of drug or alcohol abuse (defined as alcohol consumption more than&#xD;
             2 units per day on a regular basis).&#xD;
&#xD;
          8. Regular smoking (defined as more than 5 cigarettes or equivalent per week), or unable&#xD;
             to stop smoking during the study. Occasional smokers may be enrolled.&#xD;
&#xD;
          9. Excessive consumption of beverages containing xanthine bases (defined as more than 4&#xD;
             glasses per day).&#xD;
&#xD;
             Interfering substances&#xD;
&#xD;
         10. Any medication, including St John's Wort, within 14 days prior to administration of&#xD;
             the first dose or within 5 times the elimination half-life or pharmacodynamic&#xD;
             half-life of the medication, with the exception of hormonal contraception, menopausal&#xD;
             hormone replacement therapy, or occasional paracetamol at doses up to 2g/day.&#xD;
&#xD;
         11. Any consumption of grapefruit or products containing grapefruit within 5 days prior to&#xD;
             the first dose administration.&#xD;
&#xD;
         12. Any vaccination in the 28 days prior to administration of the first dose.&#xD;
&#xD;
             General conditions&#xD;
&#xD;
         13. Any participant who, in the judgment of the Investigator, is likely to be&#xD;
             non-compliant during the study, or to be unable to cooperate due to language problems&#xD;
             or poor mental development.&#xD;
&#xD;
         14. Any participant who enrolled in or participated in any other clinical study involving&#xD;
             an investigational medicinal product, or in any other type of medical research within&#xD;
             1 month or within 5 times the elimination half-life prior to administration of the&#xD;
             first dose.&#xD;
&#xD;
         15. Any participant who cannot be contacted in the case of an emergency.&#xD;
&#xD;
         16. Any participant who is the Investigator or any sub-investigator, research assistant,&#xD;
             pharmacist, study coordinator, or other staff thereof directly involved in conducting&#xD;
             the study or any person dependent on (employees or immediate family members) the study&#xD;
             site, the Investigator or the Sponsor.&#xD;
&#xD;
             Biological status&#xD;
&#xD;
         17. Positive result on any of the following tests: hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis B core antibodies (HBcAb), anti-hepatitis C virus antibodies (anti-HCV),&#xD;
             anti-human immunodeficiency virus 1 and 2 antibodiesï¼anti-HIV1 and anti-HIV2 Ab).&#xD;
&#xD;
         18. Positive alcohol test.&#xD;
&#xD;
         19. Any participant in whom venous blood collection is difficult.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang Jianfei</last_name>
    <role>Study Director</role>
    <affiliation>Nanjing Immunophage Biotech Co., Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhang Qi, doctor</last_name>
    <phone>13074800770</phone>
    <email>qzhang@immunophage.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scientia Clinical Research Ltd</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Argent</last_name>
      <phone>02 9382 5844</phone>
      <email>christopher.argent@scienticaclinicalresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

